Table 2 Geometric mean titer (GMT) for influenza strains pre-vaccine and post-vaccine
All patients (n = 226) (missinga: 24/28) | bDMARDs monotherapy (n = 80) (missinga: 8/14) | bDMARDs + DMARDs (n = 110) (missinga: 13/11) | Rituximab (n = 5) (missinga: 1/0) | Systemic disorders (n = 18) (missinga: 1/1) | Other (n = 13) (missinga: 1/2) | Controls (n = 15) (missinga: 4/2) | |
|---|---|---|---|---|---|---|---|
A/Cal H1N1pdm09 | |||||||
Pre-vaccine | 102.4 (92.1–113.9) | 110.9 (91.8–134.1) | 94.3 (81.2–109.5) | 113.1 (59.8–213.9) | 125.3 (82.6–190.1) | 89.8 (54.9–146.7) | 170.4 (100.4–289.2) |
Post-vaccine | 147.9 (79.0–165.1) | 142.5 (118.7–171.2) | 154.0 (132.1–179.6) | 105.6 (65.9–169.1) | 147.5 (86.6–251.3) | 150.2 (81.9–275.3) | 287.6 (178.2–464.4) |
A/Swi H3N2 | |||||||
Pre-vaccine | 63.0 (58.1–68.4) | 63.9 (55.2–73.9) | 61.4 (54.9–68.6) | 80.0 (32.5–196.9) | 57.7 (41.3–80.8) | 75.5 (53.3–107.1) | 70.5 (46.9–105.9) |
Post-vaccine | 87.3 (79.0–96.5) | 94.6 (79.5–112.7) | 78.9 (69.8–89.1) | 139.3 (23.9–812.7) | 90.4 (60.4–135.3) | 102.9 (52.8–200.6) | 183.6 (133.4–252.9) |
B/Phu Yamagata | |||||||
Pre-vaccine | 73.2 (67.8–78.9) | 74.8 (65.6–85.3) | 71.4 (64.1–79.5) | 67.3 (12.9–351.8) | 76.8 (57.2–103.1) | 75.5 (56.3–101.4) | 75.1 (54.2–104.1) |
Post-vaccine | 77.4 (71.2–84.1) | 75.1 (66.0–84.5) | 73.6 (66.2–81.7) | 114.5 (31.5–416.5) | 86.8 (56.2–134.0) | 102.9 (61.1–173.4) | 110.2 (76.3–159.1) |